On September 24, 2018, The Jon DeHaan Foundation presented the Cardiovascular Research Foundation (CRF) with $200 000 in support of the winner of the TCT2018 Shark Tank competition.
TCT Shark Tank is an opportunity for companies working in cardiovascular medicine to pitch their novel technologies to clinicians and industry leaders. This year’s competition saw seven companies present groundbreaking ideas that each had to potential to revolutionize some aspect of the field.
Aria CV, Inc. out of St. Paul, MN, was this year’s winner. This company has a unique approach to treating pulmonary hypertension. They are developing a permanently implantable medical balloon that will regulate blood pressure in the artery just outside of the heart. The device is designed to reduce the workload on the heart and increase blood flow which will ultimately increase exercise capacity for the patient thereby improving his/her quality of life.
Pulmonary hypertension is a chronic and debilitating condition that affects is a chronic and debilitating condition that affects people between 20 and 65 years of age. It has an untreated median survival of 2 to 3 years from the time of diagnosis with the cause of death being right ventricular failure. It has no cure. Today, the symptoms of pulmonary hypertension are managed with pharmaceuticals. Aria CV’s innovation, as Dr. Juan Granada, president and CEO of CRF states is, “a truly novel concept with potential to improve the survival and quality of life for people with heart disease.”
Dr. Robert Schwartz presented CRF and Aria CV with the award on September 24th at TCT2018 Says Dr. Schwartz, "The DeHaan Foundation is firmly committed to its major mission in supporting cardiovascular disease innovation in many forms. The partnership with the Cardiovascular Research Foundation and TCT is an ideal collaboration to further this goal.” The Jon DeHaan Foundation anticipates supporting CRF and the innovations that come out of TCT Shark Tank for many years to come.